Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study to Assess the Efficacy and Safety of DA-3002

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with Turner's Syndrome through chromosome analysis~* The chronological age: 2≤AGE≤12~* The yearly growth rate should be less than 6cm; the bone age should be equal or less than 12; the height ≤ 10th percentile for the heights of their agemates~* Before the adolescence, Tuner stage I (breast)~* Normal thyroid function~Exclusion Criteria:~* Growth hormone was administered for 12 months or longer in the past~* Treated with estrogen or adrenal androgens for 12 months or longer in the past~* Malignancy, CNS Trauma, Psychiatric Disorder

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- DA-3002 (Type: EXPERIMENTAL): 0.14 IU (0.045-0.050mg)/kg/day of DA-3002 is injected for 52 weeks by changing injecting areas
- Genotropin® (Type: ACTIVE_COMPARATOR): 0.14 IU (0.045-0.050mg)/kg/day of Genotropin is injected for 52 weeks by changing injecting areas

Based on this trial design, predict the completion outcome and termination type (if applicable).